logo-loader
viewCryptocurrency and Blockchain

Bitcoin drops to 13-month low as Bitcoin Cash split stokes uncertainty

The slump last week has driven Bitcoin's market cap to below US$100bn, a level not seen since the Bitcoin 'bubble' burst at the start of 2018

Bitcoin on keyboard
In lunchtime trading Monday, Bitcoin's price was around US$5,236, 17% lower than this time last week

The original cryptocurrency, Bitcoin, slumped to its lowest level in 13 months on Monday as uncertainty around a hard fork in Bitcoin Cash sent the digital currency sliding.

In lunchtime trading, Bitcoin's price was around US$5,236, down 5.4% on the last close and 17% lower than this time last week.

Latest split has raised concerns​

The lower price has driven the total market cap of Bitcoin below US$100bn for the first time since the Bitcoin ‘bubble’ at the end of 2017, which saw its value increase exponentially on a wave of speculation to around US$17,000 by mid-December before crashing back to around US$7,820 in early February and entering a slower decline.

The plunge began last Thursday as the market was hit by uncertainty regarding a so-called ‘hard fork’ in Bitcoin Cash into new currencies, Bitcoin ABC and Bitcoin SV.

A ‘hard fork’ is a radical change to the protocol of a blockchain system that makes previously invalid blocks/transactions valid or invalid, essentially a permanent divergence from previous versions of the blockchain.

READ: Blockchain basics: Beyond Bitcoin what can the decentralised ledger technology do?

Bitcoin Cash itself is the result of a hard fork from the original Bitcoin blockchain last year, which stemmed from disagreements on how to scale the asset.

The latest split has raised concerns that cryptocurrency miners will divert their processing power towards the new currencies and away from Bitcoin.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medexus Pharmaceuticals pleased with recent Aptevo BioTherapeutics...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) CEO Ken d’Entremont tells Proactive he's pleased with the value the acquisition of hematology asset IXINITY has provided to Medexus, and that it is well positioned to emerge stronger when the economy reopens after the coronavirus crisis....

16 hours, 11 minutes ago

2 min read